CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows from Operating Activities:
Net income	$ 24,909	$ 31,713
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	5,694	8,008
Non-cash compensation	3,273	7,347
Amortization and impairment of operating lease right of use assets	8,622	10,096
(Gain) loss on disposal of property and equipment	(70)	5
Loss on personal care divestiture	2,186	0
Deferred income taxes	2,772	3,205
Equity in (earnings) loss from equity method investments	(123)	1,403
Amortization of deferred debt issuance costs	248	248
Return on equity method investments	1,787	1,710
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(7,476)	(18,618)
Other current assets	(4,128)	7,882
Operating lease right of use assets	(918)	(749)
Other assets	(111)	247
Accounts payable	(3,457)	(2,115)
Accrued expenses	741	7,483
Other long-term obligations	(28)	(57)
Operating lease liabilities	(7,960)	(9,187)
Net cash provided by operating activities	25,961	48,621
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	19	22
Proceeds from the sale of property and equipment	0	37
Purchases of property and equipment	(1,350)	(902)
Investments in technology assets	(210)	(236)
Purchase of cost method investment	0	(15,000)
Proceeds from personal care divestiture	47,787	0
Acquisitions of businesses, net of cash acquired	(350)	0
Net cash provided by (used in) investing activities	45,896	(16,079)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	0	86
Proceeds from issuance of stock to employee stock purchase plan	816	985
Shares withheld to pay taxes on non-cash compensation	(1,308)	(4,682)
Noncontrolling interest contributions	0	652
Noncontrolling interest distributions	(285)	(672)
Proceeds from borrowings under revolving line of credit	8,000	0
Repayments of borrowings under revolving line of credit	(8,000)	0
Principal payments of long-term obligations	(55,313)	(3,771)
Purchase of noncontrolling interest	(800)	0
Net cash used in financing activities	(56,890)	(7,402)
Net increase in cash, cash equivalents and restricted cash	14,967	25,140
Cash, cash equivalents and restricted cash at beginning of period	54,133	45,769
Cash, cash equivalents and restricted cash at end of period	69,100	70,909
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	6,654	1,864
Cash paid for income taxes, net of refunds received	352	551
Cash paid for operating lease liabilities	8,878	9,936
Cash paid for finance lease liabilities	2,457	357
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	7,083	11,203
Right of use assets obtained in exchange for finance lease liabilities	20,790	216
Reductions to right of use assets resulting from reductions to operating lease liabilities	141	299
Reductions to right of use assets resulting from reductions to finance lease liabilities	369	0
Noncontrolling interest contribution	$ 0	$ 8,900